1. Home
  2. ASST vs AKBA Comparison

ASST vs AKBA Comparison

Compare ASST & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asset Entities Inc. Class B

ASST

Asset Entities Inc. Class B

HOLD

Current Price

$1.04

Market Cap

636.4M

Sector

Technology

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.49

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASST
AKBA
Founded
2020
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
636.4M
729.1M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
ASST
AKBA
Price
$1.04
$1.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$1.50
$6.25
AVG Volume (30 Days)
75.2M
2.8M
Earning Date
11-14-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,512,106.00
$225,071,000.00
Revenue This Year
N/A
$52.38
Revenue Next Year
N/A
$22.45
P/E Ratio
N/A
N/A
Revenue Growth
125.01
32.49
52 Week Low
$0.73
$1.45
52 Week High
$7.89
$4.08

Technical Indicators

Market Signals
Indicator
ASST
AKBA
Relative Strength Index (RSI) 55.15 33.61
Support Level $0.73 $1.58
Resistance Level $0.87 $1.71
Average True Range (ATR) 0.08 0.07
MACD 0.04 0.00
Stochastic Oscillator 84.76 7.41

Price Performance

Historical Comparison
ASST
AKBA

About ASST Asset Entities Inc. Class B

Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: